Summary of Team V and IX PRA 3 workshops

StartNewsSummary of Team V and IX PR...

Summary of Team V and IX PRA 3 workshops


Selection of a Suitable Animal Model in Preclinical In Vivo Studies is the title of the first meeting as part of the series “In Vivo and In Vitro Research in the Eyes of Teams V and IX in PRA 3 – a cycle of meetings about intra and inter-collegiate cooperation”, held online on 17 December this year. The meeting was attended by a total of approximately 50 persons. The patronage of the event was provided by the MUG Rector, Prof. Marcin Gruchała, and by the Fahrenheit Universities in Gdańsk.

The meeting was opened by Marta Tomczyk, Ph.D., of the MUG Department and Division of Biochemistry, the coordinator of Team V, PRA 3, who outlined the idea of regular meetings and invited the participants to take part in the next oncoming events. The lecture titled CD73 in Breast Cancer – An Enemy or a Friend? An Example of the Need to Select a Suitable Model for Preclinical Studies was delivered by Dr. Habil. Patrycja Koszałka from the Division of Cell Biology and Immunology of the MUG, the coordinator of Team V and a member of Teams IX and X in PRA 3. The second part of the webinar was devoted to topics related to the use of the complement system proteins to enhance the cytotoxic activity of immunotherapeutic drugs, which was introduced by Dr. Habil. Marcin Okrój, Associate Professor, of the MUG Division of Cell Biology and Immunology, member of Teams V, VIII and IX in PRA 3. The participants had a chance to ask questions in the chat. The speakers also encouraged contact from persons interested in the topic being raised.

The event was open, so it was not only the scientists of the Medical University of Gdańsk that had the opportunity attend. The next meeting will take place on 14 January at 1 p.m., and information about the speakers and topics of the lectures will be available soon.

The originators of the meeting cycle were the researchers of teams V In vivo studies on mechanism of disease and therapy and IX Technological developments for bioanalysis and therapy including cell based, 3D and artificial engineered models, which are a part of Priority Research Area No. 3 Biochemistry, Genetics and Molecular Biology, delineated as part of the “Excellence Initiative – Research University” programme at the Medical University of Gdańsk.